Underpinning Voyager’s mission is its trademark AAV capsid-discovery platform, Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER). This broadly applicable, functional ...

Two fundamental aspects of AAV research are the accurate quantification of AAV capsid titters and the detection of pre-existing antibodies against AAV. These measurements are essential for ensuring ...

In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.

AAV9 is known to have some natural ability to penetrate the blood-brain barrier, and researchers have generated AAV9 capsid variants that efficiently cross the blood-brain barrier and enter neurons in ...

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...

Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at treating neurological diseases. Astellas will ...

The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.